Alexandre Vivot
clinicalepidemio.fr
0000-0001-9281-3129
28 papers found
Refreshing results…
Bayesian analysis from phase III trials was underused and poorly reported: a systematic review
Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies
Transfer of Statistical Innovations of the 1990s-2000s in Oncology to the Biomedical Literature
Living network meta-analysis was feasible when considering the pace of evidence generation
Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework
Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients
Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
Mapping of Crowdsourcing in Health: Systematic Review (Preprint)
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study
Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
Clinical Benefit, Price and Approval Characteristics of FDA-approved New Drugs for Treating Advanced Solid Cancer, 2000-2015
Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?
Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults
Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up:
Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov
Association of Alzheimer’s related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study
Magnetisation transfer parameters and stroke outcome
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs
Missing publications? Search for publications with a matching author name.